NBC News (7/7, Cox) reports a study from the FDA’s Division of Applied Regulatory Science “suggests there are still ongoing questions about the safety of even low doses of cannabidiol, even as CBD capsules, gummies, edibles, oils and lotions have become increasingly omnipresent in the United States in recent years.” The researchers “carried out a randomized double-blind placebo-controlled trial last year to assess how low-dose CBD affects liver function in a group of healthy middle-aged men and women.” They observed that 5% of participants “showed greatly elevated levels of the liver enzyme aminotransferase, a known marker of liver cell damage or inflammation.” Additionally, “women appeared to be more vulnerable than men. The liver enzyme returned to normal within one or two weeks of stopping CBD.” The study was published in JAMA Internal Medicine.
Related Links:
— “Even low doses of CBD may cause harm to the liver in some people, FDA study finds,” David Cox, NBC News, July 7, 2025